Boundless Bio (BOLD)

• Market cap: $24.4M
• 1 day: 3.81%
• 5 days: -0.91%
• 1 month: -33.94%
• 3 months: -35.12%
• 6 months: -56.57%
• Year to date: -60.07%
• 1 year: -82.33%
• 5 years: -92.35%
• 10 years: -92.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 64

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1,015% more capital invested

Capital invested by funds: $37.6M [Q4 2024] → $419M (+$381M) [Q1 2025]

17.98% more ownership

Funds ownership: 58.13% [Q4 2024] → 76.11% (+17.98%) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

2% less funds holding

Funds holding: 55 [Q4 2024] → 54 (-1) [Q1 2025]

20% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 15

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 175% upside
• Avg. target: $4 267% upside
• High target: $5 359% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor	359% upside $5	Buy Initiated	2 Jun 2025
Leerink Partners Michael Cherny	175% upside $3	Market Perform Downgraded	28 May 2025